Your browser is no longer supported. Please, upgrade your browser.
ARTL [NASD]
Artelo Biosciences, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own1.20% Shs Outstand16.99M Perf Week-9.60%
Market Cap26.13M Forward P/E- EPS next Y-0.34 Insider Trans3.16% Shs Float13.95M Perf Month-11.02%
Income-5.30M PEG- EPS next Q-0.09 Inst Own19.20% Short Float12.33% Perf Quarter-30.67%
Sales- P/S- EPS this Y-25.60% Inst Trans49.41% Short Ratio0.74 Perf Half Y121.57%
Book/sh0.76 P/B1.49 EPS next Y20.90% ROA-68.40% Target Price- Perf Year-7.38%
Cash/sh0.48 P/C2.33 EPS next 5Y- ROE-72.80% 52W Range0.45 - 3.67 Perf YTD54.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-69.21% Beta3.34
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low150.55% ATR0.12
Employees4 Current Ratio19.40 Sales Q/Q- Oper. Margin- RSI (14)37.66 Volatility10.53% 9.88%
OptionableNo Debt/Eq0.00 EPS Q/Q72.50% Profit Margin- Rel Volume0.32 Prev Close1.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.31M Price1.13
Recom1.50 SMA20-10.12% SMA50-26.51% SMA2001.98% Volume737,967 Change-0.88%
Feb-12-21Initiated Ladenburg Thalmann Buy $7
May-06-21 07:00AM  
May-04-21 08:00AM  
Apr-20-21 02:02AM  
Apr-13-21 08:30AM  
Apr-12-21 08:30AM  
Mar-19-21 10:00AM  
Mar-11-21 07:10AM  
Mar-09-21 08:30AM  
Mar-02-21 08:30AM  
Feb-17-21 08:30AM  
Feb-16-21 08:30AM  
Feb-12-21 10:56AM  
Feb-08-21 08:30AM  
Feb-02-21 08:30AM  
Jan-29-21 04:05PM  
Jan-14-21 08:30AM  
Jan-05-21 08:30AM  
Dec-09-20 08:30AM  
Dec-08-20 08:30AM  
Dec-02-20 08:30AM  
Nov-23-20 08:30AM  
Nov-16-20 08:30AM  
Nov-11-20 08:30AM  
Nov-04-20 08:00AM  
Nov-02-20 05:48AM  
Oct-21-20 08:30AM  
Oct-14-20 04:05PM  
Oct-09-20 08:30AM  
Sep-29-20 08:00AM  
Sep-11-20 09:00AM  
Sep-10-20 09:15AM  
Aug-31-20 06:12PM  
Aug-26-20 09:30AM  
Aug-05-20 11:04AM  
Jul-14-20 09:25AM  
Jun-29-20 08:30AM  
Jun-03-20 09:30AM  
09:00AM  
May-12-20 09:30AM  
May-06-20 09:09AM  
Apr-14-20 08:30AM  
Mar-23-20 09:00AM  
Mar-02-20 09:07AM  
Feb-24-20 09:00AM  
Feb-03-20 11:42AM  
08:30AM  
Jan-29-20 09:00AM  
Jan-14-20 08:00AM  
Dec-09-19 08:30AM  
Nov-25-19 08:00AM  
Nov-18-19 08:30AM  
Nov-14-19 09:00AM  
Oct-29-19 08:30AM  
Oct-22-19 09:00AM  
Sep-18-19 08:00AM  
Sep-11-19 09:00AM  
Sep-04-19 01:34PM  
Jul-15-19 04:01PM  
Jul-10-19 07:23AM  
Jun-25-19 01:00PM  
May-08-19 04:05PM  
Jan-03-19 07:00AM  
Oct-09-18 08:00AM  
Jul-03-18 08:00AM  
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gorgas Gregory D.Pres, CEO, CFO, Treas & SecrApr 16Buy1.158,5009,809270,676Apr 20 04:10 PM